Literature DB >> 24512667

EMA response to ECCO position statement on biosimilars.

Silvio Danese, Fernando Gomollon, Pierre Michetti.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24512667     DOI： 10.1016/j.crohns.2014.01.017

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  1 in total

Review 1.  Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.

Authors:  Jørgen Jahnsen
Journal:  Therap Adv Gastroenterol       Date:  2016-03-21       Impact factor: 4.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.